Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Stage of Development | 8 | 1 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Therapy Area | 9 | 1 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Indication | 10 | 2 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Companies | 14 | 3 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Products under Development by Universities/Institutes | 17 | 2 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Therapeutics Assessment | 19 | 5 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 1 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 1 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Companies Involved in Therapeutics Development | 24 | 5 |
| Aurigene Discovery Technologies Limited | 24 | 1 |
| Beta Pharma, Inc. | 25 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 26 | 1 |
| Syros Pharmaceuticals, Inc. | 27 | 1 |
| Tragara Pharmaceuticals, Inc. | 28 | 1 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Drug Profiles | 29 | 19 |
| BS-181L Drug Profile | 29 | 1 |
| CYC-065 Drug Profile | 30 | 3 |
| sapacitabine + seliciclib Drug Profile | 33 | 3 |
| seliciclib Drug Profile | 36 | 2 |
| Small Molecule to Inhibit CDK7 for Oncology Drug Profile | 38 | 1 |
| Small Molecule to Inhibit CDK7 for Small Cell Lung Cancer Drug Profile | 39 | 1 |
| Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases Drug Profile | 40 | 1 |
| SY-1365 Drug Profile | 41 | 2 |
| SY-351 Drug Profile | 43 | 2 |
| TG-02 Drug Profile | 45 | 3 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Dormant Projects | 48 | 1 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Discontinued Products | 49 | 1 |
| Cyclin-Dependent Kinase 7 (39 kDa Protein Kinase or CDK-Activating Kinase 1 or TFIIH Basal Transcription Factor Complex Kinase Subunit or EC 2.7.11.22) Featured News &Press Releases | 50 | 12 |
| Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association | 50 | 1 |
| Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO | 51 | 1 |
| May 19, 2016: Cyclacel s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting | 52 | 1 |
| May 19, 2016: Syros Pharmaceuticals to Present on SY-1365 at 21st Congress of the European Hematology Association | 53 | 1 |
| Apr 20, 2016: Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti-Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia | 53 | 1 |
| Apr 18, 2016: Cyclacel s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors | 54 | 1 |
| Apr 15, 2016: Aurigene to Present its CDK7 Covalent Inhibitor Program at AACR Annual Conference | 55 | 1 |
| Mar 16, 2016: Syros Pharmaceuticals to Present Preclinical Data on CDK7 Inhibitor Program in Blood Cancers at Upcoming AACR Annual Meeting | 56 | 1 |
| Dec 14, 2015: Molecular Basis for Development of Cyclacel s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium | 57 | 1 |
| Dec 05, 2015: Syros Pharmaceuticals Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of First-in-Class Selective CDK7 Inhibitor in Models of Acute Leukemias | 57 | 1 |
| Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models | 58 | 1 |
| Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference | 59 | 1 |
| Nov 05, 2015: Syros Pharmaceuticals to Present Preclinical Data on First-in-Class Selective CDK7 Inhibitor Program at American Society of Hematology Annual Meeting | 60 | 1 |
| Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference | 60 | 1 |
| Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors | 61 | 1 |
| Appendix | 62 | 2 |
| Methodology | 62 | 1 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 62 | 1 |
| Contact Us | 62 | 1 |
| Disclaimer | 63 | 1 |